Skip to main content
Explore Pipeline Explore Pipeline Events Events Download Download Resources

Oncology Pipeline

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. In 2019 Lilly created Loxo Oncology at Lilly, with the goal of rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating new medicines that work in early clinical development and will matter to patients.

Molecule Overview
Clinical Trials
Download Download Flash Card

RET Inhibitor

Selpercatinib, LOXO-292

RET_Inhibitor

Mulligan LM1

Target
Rearranged during transfection (RET) fusions have been identified in approximately 2% of non-small cell lung cancer,2,3 10% to 20% of papillary thyroid cancer,4,5 and a subset of colon and other cancers.6-8 RET point mutations account for approximately 60% of medullary thyroid cancer.9-11 Cancers that harbor activating RET fusions or RET mutations depend primarily on this single constitutively activated kinase for their proliferation and survival. This dependency renders such tumors highly susceptible to small molecule inhibitors targeting RET.
Molecule
Selpercatinib (LOXO-292) is a highly selective, potent small-molecule inhibitor of RET. Selpercatinib possesses nanomolar potency against diverse RET alterations, including RET fusions, activating RET point mutations, and acquired resistance mutations. Selpercatinib has been shown in vitro and in vivo to exhibit high selectivity for RET, with limited activity against other tyrosine kinases.12,13
Clinical Development
Selpercatinib is being investigated in clinical trials in patients with medullary thyroid cancer, non-small cell lung cancer, papillary thyroid carcinoma, pediatric cancer, or other advanced solid tumors.

References

  1. Mulligan LM. Nat Rev Cancer. 2014;14:173-186.
  2. Lipson D, et al. Nat Med. 2012;18(3):382-384.
  3. Takeuchi K, et al. Nat Med. 2012;18(3):378-381.
  4. Bounacer A, et al. Oncogene. 1997;15(11):1263-1273.
  5. Prescott JD, Zeiger MA. Cancer. 2015;121(13):2137-2146.
  6. Ballerini P, et al. Leukemia. 2012;26(11):2384-2389.
  7. Bossi D, et al. Mol Oncol. 2014;8(2):221-231.
  8. Stransky N, et al. Nat Commun. 2014;5:4846.
  9. Hofstra RM, et al. Nature. 1994;367(6461):375-376.
  10. Agrawal N, et al. J Clin Endocrinol Metab. 2013;98(2):E364-E369.
  11. Taccaliti A, et al. Curr Genomics. 2011;12(8):618-625.
  12. Subbiah V, et al. Ann Oncol. 2018;29:1869-1876.
  13. Drilon A, et al. LIBRETTO-001: A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. Presented at: ASCO Annual Meeting; June 1-5, 2018; Chicago, IL.

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

View All Trials For This Molecule
DISCOVER OTHER MOLECULES

CDK4 & 6 Inhibitor

Learn More

CD73 Inhibitor

Learn More

Selective ER Degrader

Learn More